CUSP for VAP: EVAP Where are we g oing and How w ill w e get there?

43
© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 CUSP for VAP: EVAP Where are we going and How will we get there? Sean Berenholtz M.D., MHS

description

CUSP for VAP: EVAP Where are we g oing and How w ill w e get there? . Sean Berenholtz M.D., MHS. Healthcare-Associated Infections (HAI): A Preventable Epidemic. Focus on 4 HAIs: VAP, CLABSI, surgical site infections and catheter associated urinary tract infections - PowerPoint PPT Presentation

Transcript of CUSP for VAP: EVAP Where are we g oing and How w ill w e get there?

Page 1: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011

CUSP for VAP: EVAPWhere are we going and How will we get there?

Sean Berenholtz M.D., MHS

Page 2: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?
Page 3: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

3Armstrong Institute for Patient Safety and Quality

Page 4: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

4

Healthcare-Associated Infections (HAI): A Preventable Epidemic

• Focus on 4 HAIs: – VAP, CLABSI, surgical site infections and

catheter associated urinary tract infections• $5 billion per year excess costs• 1.7 million patients per year

– 1 out of 20 patients• 98,000 deaths per year

– As many deaths as breast cancer and HIV/AIDS– 6th leading cause of preventable deaths

Waxman HA. Hearing of April 16, 2008

Page 5: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Impact of VAP

• 10-20% of ventilated patients• Common HAI

– Median rate 1-4.3 per 1000 vent day– 250,000 infections per year

• Most lethal HAI– Mortality likely exceeds 10%– Up to 36,000 deaths per year

• Cost per episode: $23,000Safdar CCM 2005, Kollef Chest 2005,Perencevich ICHE 2007, Klevens Public Health Rep. 2007.

Page 6: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Project Overview

• NIH/NHLBI and AHRQ funding project– Individual hospitals participate for 3 years,

including 2 year intervention period and 1 year evaluation of sustainability

• Leveraging leaders in field – Armstrong Institute for Patient Safety and

Quality, NIH/NHLBI, CDC, AHRQ, University of Pennsylvania, MHA and HAP

– MD and PA hospitals

Armstrong Institute for Patient Safety and Quality6

Page 7: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Project Goals

• To achieve significant reductions in VAP/VAE rates

• To achieve significant improvements in safety culture

Page 8: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

How will we get there?

http://www.hopkinsmedicine.org/armstrong_institute

Page 9: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Successful Efforts to Reduce Preventable Harm

• Michigan Keystone ICU program– Reductions in central line-associated

blood stream infections (CLABSI) 1,2

– Reductions in ventilator-associated pneumonias (VAP) 3

• National On the CUSP: Stop BSI program 4

1. Pronovost P, N Engl J Med 2006;355:2725-32. 2. Pronovost P, BMJ 2010;340:c309. 3. Berenholtz S, Infect Control Hosp Epidemiol. 2011;32(4): 305-314. 4. www.onthecuspstophai.org

9

Page 10: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Percent of Units with Zero CLABSIs and Achieving Project Goal (<1/1000 CL days)

10

*Data drawn from Interim Project Report – Figure 5 – Cohorts 1 through 3

www.onthecuspstophai.org

Page 11: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Ventilator Bundle

• Semirecumbant positioning

• Appropriate SUD prophylaxis

• Appropriate DVT prophylaxis

• Appropriate sedation

• Daily assessment of readiness to extubate

Page 12: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Sample Daily Goals

J Crit Care 2003;18(2):71-75

Education

Decrease complexity and create redundancy

• Daily goals checklist

• Standardized ordersets and protocols

Independent redundancies

• Nursing, RT, families

Page 13: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Ventilator Bundle Adherence Through 36-months Post-Intervention

Infect Control Hosp Epidemiol. 2011;32(4): 305-314.

Page 14: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Mean Quarterly VAP Rate Through 36-Months Post-Intervention

Infect Control Hosp Epidemiol. 2011;32(4): 305-314.

Page 15: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Lives and Dollars Saved

• 10% mortality reduction – Michigan Medicare data compared to over

350 hospitals in surrounding states• BMJ 2011;342:d219

• $1.1 million saved per year for average hospital– 30 CLABSIs and 18 VAP cases averted

annually– Financial benefits far exceed costs of

intervention• Am J Med Qual. 2001;26:333-339 15

Page 16: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Lessons Learned

• Harm is preventable– Many healthcare acquired infection are

preventable; should be viewed as defect

• Focus on systems; Not individuals

• Limitations of the ‘Ventilator Bundle’

Page 17: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

17

Ventilator Bundle

• Developed to prevent complications for patients requiring MV– Not focused specifically on VAP prevention – Not systematically updated

• VAP prevention guidelines conflicting and outdated

• Need to develop a ‘VAP prevention’ bundle– Pilot test before national dissemination

Armstrong Institute for Patient Safety and Quality

Page 18: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

VAP Prevention Guidelines

• CDC Guidelines • MMWR Recomm Rep. 2004;53:1-36

• American Thoracic Society/ Infectious Diseases Society of America

• AJRCCM 2005;171(4):388-416.• Canadian VAP Prevention Guidelines

• J Crit Care 2008;23(1):138-147.• Society for Healthcare Epidemiology of

America• ICHE 2008;29:S31-S40.

Armstrong Institute for Patient Safety and Quality

Page 19: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Process Measures: Daily Evaluation1. Head of Bed Elevation (HOB)

– Use of a semi-recumbent position ( ≥ 30 degrees).

2. Spontaneous Awakening and Breathing Trials (SAT & SBT)

– Make a daily assessment of readiness to wean with the use of the SAT and SBT.

3. Oral Care– At least 6 times per day

4. Oral Care with Chlorhexidine– 2 times per day

5. Subglottic Suctioning – Use CSS ETTs in patients expected

to be MV for >72 hoursArmstrong Institute for Patient Safety and Quality19

Page 20: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Policy Based Structural Measures :

1. Use a closed ETT suctioning system2. Change close suctioning catheters only as needed3. Change ventilator circuits only if damaged or soiled4. Change HME every 5-7 days and as clinically indicated5. Provide easy access to NIVV equipment and institute protocols to promote use6. Periodically remove condensate from circuits, keeping the circuit closed during

the removal, taking precautions not to allow condensate to drain toward patient7. Use early mobility protocol8. Perform hand hygiene9. Avoid supine position10. Use standard precautions while suctioning respiratory tract secretions11. Use orotracheal intubation instead of nasotracheal12. Avoid use of prophylactic systemic antimicrobials13. Avoid non-essential tracheal suctioning14. Avoid gastric over-distention

20ETT endotrachael tube; HME heat moist exchanger; NIVV non-invasive ventilation

Page 21: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

21

Early Ambulation

• RCT, 104 MICU patients on ventilators• PT/OT starting at day 1-2 vs ‘usual care’

– Passive range of motion to ambulation• Improved return to independent functional

status at hospital discharge• Shorter duration of delirium • Increased ventilator-free days

Armstrong Institute for Patient Safety and Quality

Lancet 2009; 373: 1874–82

Page 22: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

22

Far More Complex than Implementing a Checklist

• Technical work– ‘Things we have a solution to’– Summarize the evidence and educate

providers

• Adaptive work– Addressing values, attitudes and beliefs

that drive actions– Teamwork and safety culture is important and

can be improved

Armstrong Institute for Patient Safety and Quality

Page 23: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?
Page 24: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011

L&D RN/MD ICU RN/MD OR RN/Surg CRNA/Anesth

Page 25: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

25

Page 26: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

26

Teamwork and Safety Culture

• Linked to important clinical and operational outcomes

• Predicts successful efforts to implement safety programs

• Responsive to interventions like CUSP

Armstrong Institute for Patient Safety and Quality

Page 27: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

27

 

"Needs Improvement” Statewide Michigan CUSP ICU Results

• “Needs Improvement”: Less than 60% of respondents reporting good safety or teamwork climate

• Statewide in 2004 82-84% needed improvement, in 2007 22-23%

J Critical Care 2008;23:207-221

Crit Care Med 2011;39(5):1-6

Page 28: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Comprehensive Unit-based Safety Program (CUSP)

1. Educate staff on science of safety

2. Identify defects

3. Assign executive to adopt unit

4. Learn from one defect per quarter

5. Implement teamwork tools Jt Comm J Qual Patient Saf

2010;36:252-60 Resources: www.safercare.net

Page 29: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Sample Daily Goals

J Crit Care 2003;18(2):71-75

Education

Decrease complexity and create redundancy

• Daily goals checklist

• Standardized ordersets and protocols

Independent redundancies

• Nursing, RT, families

Page 30: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Best Way Forward

• Informed by science

• Led by clinicians and supported by management

• Guided by measures

Armstrong Institute for Patient Safety and Quality30

Page 31: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Advancing the Science

• Development of a ‘VAP Prevention’ bundle– Updating the ‘Ventilator Bundle’ to focus on VAP– Advancing science of process measurement

• CDC NHSN VAP definition is changing– Ventilator-Associated Event (VAE) algorithm

• Identification of contextual variables– Ethnographic studies

Page 32: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?
Page 33: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011

Today is going to be a good day: Overview

Page 34: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

Overview of the Day

• Details and requirements of the effort • Targeted topics to build unit plans

– Sr. Leader, – Physician, and – Patient and Family engagement

• Networking and planning to develop a unit level plan of action

• Data Collection and Data Entry Requirements • Introduction of CECity Platform

– Real time reporting, LMS, Social networking• Summary, Next Steps, and Adjourn

Armstrong Institute for Patient Safety and Quality34

Page 35: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

35

References-1

Slide 4Waxman, HA.  Healthcare-associated infections: A preventable epidemic.  Hearing, April 16, 2008;  House of Representatives, Committee on Oversight and Government Reform, Washington DC. 

Slide 5Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005 Oct;33(10):2184-93.Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005 Dec;128(6):3854-62. Perencevich EN, Stone PW, Wright SB, Carmeli Y, Fishman DN, Cosgrove SE: Society for Healthcare Epidemiology of America. Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol. 2007 Oct;28(10):1121-33.

Armstrong Institute for Patient Safety and Quality

Page 36: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

36

References-2

Slide 5, continuedKlevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, Cardo DM. Estimating health care-associated infections and deaths in U. S. hospitals, 2002. Public Health Rep. 2007 Mar-Apr;122(2):160-6.

Slide 8http://www.hopkinsmedicine.org/armstrong_institute

Slide 9Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, Sexton B, Hyzy R, Welsh R, Roth G, Bander J, Kepros J, Goeschel C. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006 Dec 28;355(26):2725-32.

Armstrong Institute for Patient Safety and Quality

Page 37: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

37

References-3

Slide 9, continuedPronovost PJ, Goeschel CA, Colantuoni E, Watson S, Lubomski LH, Berenholtz SM, Thompson DA, Sinopoli DJ, Cosgrove S, Sexton JB, Marsteller JA, Hyzy RC, Welsh R, Posa P, Schumacher K, Needham D. Sustaining reductions in catheter related bloodstream infections in Michigan intensive care units: observational study. BMJ. 2010 Feb 4;340:c309.Berenholtz SM, Pham JC, Thompson DA, Needham DM, Lubomski LH, Hyzy RC, Welsh R, Cosgrove SE, Sexton JB, Colantuoni E, Watson SR, Goeschel CA, Pronovost PJ. Collaborative cohort study of an intervention to reduce ventilator-associated pneumonia in the intensive care unit. Infect Control Hosp Epidemiol. 2011 Apr;32(4):305-14.www.onthecuspstophai.org

Armstrong Institute for Patient Safety and Quality

Page 38: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

38

References-4

Slide 10 www.onthecuspstophai.org

Slide 12Pronovost P, Berenholtz S, Dorman T, Lipsett PA, Simmonds T, Haraden C. Improving communication in the ICU using daily goals. J Crit Care. 2003 Jun;18(2):71-5.

Slide 13Berenholtz SM, Pham JC, Thompson DA, Needham DM, Lubomski LH, Hyzy RC, Welsh R, Cosgrove SE, Sexton JB, Colantuoni E, Watson SR, Goeschel CA, Pronovost PJ. Collaborative cohort study of an intervention to reduce ventilator-associated pneumonia in the intensive care unit. Infect Control Hosp Epidemiol. 2011 Apr;32(4):305-14.

Armstrong Institute for Patient Safety and Quality

Page 39: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

39

References-5

Slide 14Berenholtz SM, Pham JC, Thompson DA, Needham DM, Lubomski LH, Hyzy RC, Welsh R, Cosgrove SE, Sexton JB, Colantuoni E, Watson SR, Goeschel CA, Pronovost PJ. Collaborative cohort study of an intervention to reduce ventilator-associated pneumonia in the intensive care unit. Infect Control Hosp Epidemiol. 2011 Apr;32(4):305-14.

Slide 15Lipitz-Snyderman A, Steinwachs D, Needham DM, Colantuoni E, Morlock LL, Pronovost PJ. Impact of a statewide intensive care unit quality improvement initiative on hospital mortality and length of stay: retrospective comparative analysis. BMJ. 2011 Jan 28;342:d219.Waters HR, Korn R Jr, Colantuoni E, Berenholtz SM, Goeschel CA, Needham DM, Pham JC, Lipitz-Snyderman A, Watson SR, Posa P, Pronovost PJ. The business case for quality: economic analysis of the Michigan Keystone Patient Safety Program in ICUs. Am J Med Qual. 2011 Sep-Oct;26(5):333-9.

Armstrong Institute for Patient Safety and Quality

Page 40: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

40

References-6

Slide 18 Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare

Infection Control Practices Advisory Committee. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004 Mar 26;53z(RR-3):1-36.American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare associated pneumonia. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416.Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D; VAP Guidelines Committee and the Canadian Critical Care Trials Group. J Crit Care. 2008 Mar;23(1):138-47.

Armstrong Institute for Patient Safety and Quality

Page 41: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

41

References-7

Slide 18, continuedCoffin SE, Klompas M, Classen D, Arias KM, Podgorny K, Anderson DJ, Burstin H, Calfee DP, Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Lo E, Marschall J, Mermel LA, Nicolle L, Pegues DA, Perl TM, Saint S, Salgado CD, Weinstein RA, Wise R, Yokoe DS. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol. 2008 Oct;29 Suppl 1:S31-40.

Slide 19Zolfaghari PS, Wyncoll DL. The tracheal tube: gateway to ventilator-associated pneumonia. Crit Care. 2011;15(5):310. Epub 2011 Sep 29. Speck K. Not published. The Johns Hopkins University School of Medicine.Calleamanecer (Own work) [CC-BY-SA-3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons http://commons.wikimedia.org/wiki/File%3AClinicians_in_Intensive_Care_Unit.jpg

Armstrong Institute for Patient Safety and Quality

Page 42: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

42

References-8

Slide 20ETT endotrachael tube; HME heat moist exchanger; NIVV non-

invasive ventilationSlide 21

Lancet 2009; 373: 1874–82

Armstrong Institute for Patient Safety and Quality

Page 43: CUSP  for VAP: EVAP Where  are  we  g oing  and How w ill  w e  get there?

43

References-9

Slide 27

J Crit Care 2008;23:207-22; Crit Care Med 2011;39(5):1-6

Slide 28Jt Comm J Qual Patient Saf 2010;36:252-60Resources: www.safercare.net

Slide 29J Crit Care 2003;18(2):71-75

Armstrong Institute for Patient Safety and Quality